Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
Patients with B-cell lymphoma who relapse after autologous transplant tend to have a poor
prognosis. Currently, there is no standard treatment for such patients. Bexxar is a
radioactive antibody therapy that has shown a 60-80% response rate in non-transplanted
patients with relapsed B-cell lymphoma. This study will test the safety and efficacy of
Bexxar in the treatment of patients whose B-cell lymphoma has relapsed after an autologous
transplant.